<DOC>
	<DOCNO>NCT01738282</DOCNO>
	<brief_summary>The purpose study assess efficacy Xylka® ( baclofen ) compare placebo continuous abstinence rate 20 week treatment , withdrawal , alcohol dependent patient receive Brenda therapy session .</brief_summary>
	<brief_title>Efficacy Safety Baclofen Maintenance Abstinence Alcohol Dependent Patients</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Adult patient meet DSM IV ( Diagnosis Statistical Manual Mental Disorders , 4th edition ) criterion alcohol dependence Willing participate study express desire achieve objective continuous long term abstinence withdrawal Abstinent ( last drinking ) minimum 3 day maximum 14 day At least one previous abstinence attempt Need stay end withdrawal period health care rehabilitation institution specialize addiction Need heavy psychosocial hospital care History baclofen intake , prescription self medication Porphyria Concomitant treatment one several drug maintenance abstinence Severe renal , cardiac pulmonary disorder Epilepsy history epilepsy Concomitant treatment psychotropic drug , except antidepressant stable dose 2 month , diazepam oxazepam Severe psychiatric disease ( schizophrenia bipolar disorder ) Suicidal risk history suicide Clinically significant cognitive disorder Hepatic encephalopathy Ongoing dependence within last 12 month addictive substance ( opioid , cocaine , cannabis , substance drugs… ) , except tobacco</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>baclofene</keyword>
	<keyword>Alcohol dependence</keyword>
	<keyword>Maintenance abstinence</keyword>
</DOC>